{"id":51369,"date":"2025-12-18T13:37:17","date_gmt":"2025-12-18T05:37:17","guid":{"rendered":"https:\/\/flcube.com\/?p=51369"},"modified":"2025-12-18T13:37:18","modified_gmt":"2025-12-18T05:37:18","slug":"everest-lerodalcibep-pcsk9-fda-approval-targets-china-launch","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51369","title":{"rendered":"Everest lerodalcibep PCSK9 FDA Approval Targets China Launch"},"content":{"rendered":"\n<p><strong>Everest Medicines Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1952:HKG\">HKG: 1952<\/a>) announced that the <strong>U.S. FDA<\/strong> has approved the Biologics License Application (BLA) for <strong>LEROCHOL<\/strong> (lerodalcibep-liga), a novel third\u2011generation <strong>PCSK9 inhibitor<\/strong> from LIB Therapeutics, for lowering LDL\u2011C in adults with hypercholesterolemia. This approval accelerates the path for <strong>Everest<\/strong> to bring the first PCSK9 fusion protein to the <strong>Greater China<\/strong> market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-structure-amp-regional-rights\">Partnership Structure &amp; Regional Rights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Partner<\/th><th>Role<\/th><th>Territory<\/th><th>Rights Acquired<\/th><\/tr><\/thead><tbody><tr><td><strong>LIB Therapeutics<\/strong><\/td><td>Original developer<\/td><td>Global<\/td><td>US\/EU development<\/td><\/tr><tr><td><strong>Hasten Biopharm<\/strong><\/td><td>China licensee<\/td><td>Greater China<\/td><td>Development &amp; commercialization rights (acquired Sept\u202f2023)<\/td><\/tr><tr><td><strong>Everest Medicines<\/strong><\/td><td>Strategic collaborator<\/td><td>Greater China<\/td><td>Multi\u2011drug partnership including lerodalcibep (signed Dec\u202f2025)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Drug Class<\/strong>: Third\u2011generation <strong>PCSK9 inhibitor fusion protein<\/strong><\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Small\u2011molecule protein\u2011binding technology reduces LDL\u2011C by blocking PCSK9\u2011mediated LDL receptor degradation<\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: <strong>Low immunogenicity<\/strong> and <strong>outstanding safety<\/strong> vs. monoclonal antibody PCSK9 inhibitors<\/li>\n\n\n\n<li><strong>Dosing<\/strong>: Designed for long\u2011term maintenance of LDL\u2011C control goals<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-global-regulatory-timeline\">Global Regulatory Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Status<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>United States<\/strong><\/td><td>BLA approved<\/td><td>Dec\u202f2025<\/td><\/tr><tr><td><strong>European Union<\/strong><\/td><td>Marketing authorization submitted<\/td><td>Under review<\/td><\/tr><tr><td><strong>Greater China<\/strong><\/td><td>BLA submission planned<\/td><td>H1\u202f2026<\/td><\/tr><tr><td><strong>China Launch<\/strong><\/td><td>Earliest possible approval &amp; launch<\/td><td>2027<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-strategic-outlook\">Market Opportunity &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Population<\/strong>: <strong>180 million<\/strong> adults with hypercholesterolemia in China; <strong>2 million<\/strong> with HeFH<\/li>\n\n\n\n<li><strong>PCSK9 Market<\/strong>: China PCSK9 inhibitor market projected to exceed <strong>$2 billion<\/strong> by 2028<\/li>\n\n\n\n<li><strong>Competitive Advantage<\/strong>: Lerodalcibep is the <strong>first PCSK9 fusion protein<\/strong>; offers potential for improved safety and patient compliance<\/li>\n\n\n\n<li><strong>Reimbursement Path<\/strong>: FDA approval strengthens case for priority review in China; may accelerate national insurance listing<\/li>\n\n\n\n<li><strong>Investment Thesis<\/strong>: Everest&#8217;s strategic collaboration positions it to capture premium share of China&#8217;s growing lipid\u2011lowering market<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding lerodalcibep&#8217;s regulatory submissions, commercial launch timelines, and market potential. Actual results may differ due to regulatory, competitive, and market access uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Everest Medicines Limited (HKG: 1952) announced that the U.S. FDA has approved the Biologics License&#8230;<\/p>\n","protected":false},"author":1,"featured_media":51370,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[69,126,1164,15],"class_list":["post-51369","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cvd","tag-everest-medicines","tag-hkg-1952","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Everest lerodalcibep PCSK9 FDA Approval Targets China Launch - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Everest Medicines Limited (HKG: 1952) announced that the U.S. FDA has approved the Biologics License Application (BLA) for LEROCHOL (lerodalcibep-liga), a novel third\u2011generation PCSK9 inhibitor from LIB Therapeutics, for lowering LDL\u2011C in adults with hypercholesterolemia. This approval accelerates the path for Everest to bring the first PCSK9 fusion protein to the Greater China market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=51369\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Everest lerodalcibep PCSK9 FDA Approval Targets China Launch\" \/>\n<meta property=\"og:description\" content=\"Everest Medicines Limited (HKG: 1952) announced that the U.S. FDA has approved the Biologics License Application (BLA) for LEROCHOL (lerodalcibep-liga), a novel third\u2011generation PCSK9 inhibitor from LIB Therapeutics, for lowering LDL\u2011C in adults with hypercholesterolemia. This approval accelerates the path for Everest to bring the first PCSK9 fusion protein to the Greater China market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=51369\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-18T05:37:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-18T05:37:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1803.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51369#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51369\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Everest lerodalcibep PCSK9 FDA Approval Targets China Launch\",\"datePublished\":\"2025-12-18T05:37:17+00:00\",\"dateModified\":\"2025-12-18T05:37:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51369\"},\"wordCount\":303,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51369#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1803.webp\",\"keywords\":[\"CVD\",\"Everest Medicines\",\"HKG: 1952\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51369#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51369\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=51369\",\"name\":\"Everest lerodalcibep PCSK9 FDA Approval Targets China Launch - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51369#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51369#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1803.webp\",\"datePublished\":\"2025-12-18T05:37:17+00:00\",\"dateModified\":\"2025-12-18T05:37:18+00:00\",\"description\":\"Everest Medicines Limited (HKG: 1952) announced that the U.S. FDA has approved the Biologics License Application (BLA) for LEROCHOL (lerodalcibep-liga), a novel third\u2011generation PCSK9 inhibitor from LIB Therapeutics, for lowering LDL\u2011C in adults with hypercholesterolemia. This approval accelerates the path for Everest to bring the first PCSK9 fusion protein to the Greater China market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51369#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51369\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51369#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1803.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1803.webp\",\"width\":1080,\"height\":608,\"caption\":\"Everest lerodalcibep PCSK9 FDA Approval Targets China Launch\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51369#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Everest lerodalcibep PCSK9 FDA Approval Targets China Launch\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Everest lerodalcibep PCSK9 FDA Approval Targets China Launch - Insight, China&#039;s Pharmaceutical Industry","description":"Everest Medicines Limited (HKG: 1952) announced that the U.S. FDA has approved the Biologics License Application (BLA) for LEROCHOL (lerodalcibep-liga), a novel third\u2011generation PCSK9 inhibitor from LIB Therapeutics, for lowering LDL\u2011C in adults with hypercholesterolemia. This approval accelerates the path for Everest to bring the first PCSK9 fusion protein to the Greater China market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=51369","og_locale":"en_US","og_type":"article","og_title":"Everest lerodalcibep PCSK9 FDA Approval Targets China Launch","og_description":"Everest Medicines Limited (HKG: 1952) announced that the U.S. FDA has approved the Biologics License Application (BLA) for LEROCHOL (lerodalcibep-liga), a novel third\u2011generation PCSK9 inhibitor from LIB Therapeutics, for lowering LDL\u2011C in adults with hypercholesterolemia. This approval accelerates the path for Everest to bring the first PCSK9 fusion protein to the Greater China market.","og_url":"https:\/\/flcube.com\/?p=51369","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-18T05:37:17+00:00","article_modified_time":"2025-12-18T05:37:18+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1803.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=51369#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=51369"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Everest lerodalcibep PCSK9 FDA Approval Targets China Launch","datePublished":"2025-12-18T05:37:17+00:00","dateModified":"2025-12-18T05:37:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=51369"},"wordCount":303,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=51369#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1803.webp","keywords":["CVD","Everest Medicines","HKG: 1952","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=51369#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=51369","url":"https:\/\/flcube.com\/?p=51369","name":"Everest lerodalcibep PCSK9 FDA Approval Targets China Launch - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=51369#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=51369#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1803.webp","datePublished":"2025-12-18T05:37:17+00:00","dateModified":"2025-12-18T05:37:18+00:00","description":"Everest Medicines Limited (HKG: 1952) announced that the U.S. FDA has approved the Biologics License Application (BLA) for LEROCHOL (lerodalcibep-liga), a novel third\u2011generation PCSK9 inhibitor from LIB Therapeutics, for lowering LDL\u2011C in adults with hypercholesterolemia. This approval accelerates the path for Everest to bring the first PCSK9 fusion protein to the Greater China market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=51369#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=51369"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=51369#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1803.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1803.webp","width":1080,"height":608,"caption":"Everest lerodalcibep PCSK9 FDA Approval Targets China Launch"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=51369#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Everest lerodalcibep PCSK9 FDA Approval Targets China Launch"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1803.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51369","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=51369"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51369\/revisions"}],"predecessor-version":[{"id":51371,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51369\/revisions\/51371"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/51370"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=51369"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=51369"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=51369"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}